GO
Loading...

Biotechnology

More

  • Cramer's Top Dividend Stocks 2012 Monday, 30 Apr 2012 | 9:27 AM ET
    Whether or not the stock market continues to rally, Jim Cramer recommends investors seek the protection of stocks with serious dividends. After all, if the stock market falls and the economy worsens, dividend-paying stocks will pay investors to wait until things get better. The "Mad Money" host especially likes “accidental high-yielders” — the stocks with small payouts that wouldn’t ordinarily offer high yields. Because of downward pressure in the markets, which has hurt their share prices, thos

    We pulled together a list of Cramer's favorite dividend plays. Read on and pick one or two for your portfolio. They could offer just the kind of defense that you need.

  • Spotlight: Energy Monday, 23 Apr 2012 | 1:05 PM ET
    Wind farm in Evia, Greece

    There are too many options but no one solution to the energy problem. Our needs are many. The current alternative energies — solar, wind, biofuels, nuclear and geothermal — all have limitations, but they're worth it until something better comes along.

  • Sanofi-Aventis CEO: We've Been Quick to Move Friday, 13 Apr 2012 | 10:50 AM ET

    Sanofi-Aventis has been quick to move before its patents on bestselling products expired, said CEO Chris Viehbacher.

  • Cramer's Growth Play on Celgene     Thursday, 12 Apr 2012 | 6:45 PM ET

    Mad Money's Cramer runs through a ten-point checklist to see if Celgene is in a position to deliver growth to investors.

  • The Trade Behind Allergan's Pullback, Cramer     Thursday, 12 Apr 2012 | 6:25 PM ET

    Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.

  • Celgene Riding Molecular Biology 'Revolution': CEO Thursday, 12 Apr 2012 | 5:31 PM ET
    E. Coli

    Investors are suddenly hot for biotechnology, and that helps Celgene, CEO Robert Hugin told CNBC Thursday.

  • Celgene CEO on Health Care Growth     Thursday, 12 Apr 2012 | 3:20 PM ET

    The S&P Biotech Index is up more than 10 percent and Celgene is one of its biggest gainers. Robert Hugin, Celgene chairman & CEO, discusses what's driving the company's growth, including its recent acquisition of Avila Therapeutics.

  • Bullish on Biotechs     Wednesday, 4 Apr 2012 | 2:34 PM ET

    Keryx Biopharma is down more than 70 percent after one of its colon cancer drugs failed a late stage clinical trial, with Mark Tepper, Strategic Wealth Partners managing partner.

  • Next Generation Cholesterol Drugs     Monday, 26 Mar 2012 | 11:37 AM ET

    Discussing the early trial results of the next-generation cholesterol lowering drugs, with Tony Butler, Barclay's managing director/pharmaceuticals analyst.

  • CNBC's Seema Mody has the details on Regeneron Pharmaceuticals and Amgen releasing data on injectable drugs.

  • The Future of Illumina     Tuesday, 6 Mar 2012 | 4:52 PM ET

    Jay Flatley, Illumina CEO, discusses fending off Roche's unsolicited bid as well as the future of his company.

  • Most Productive Cities Tuesday, 28 Feb 2012 | 5:52 PM ET
    The Brookings Institution recently issued a report the compared per-capita gross domestic product and changes in employment data from 2010 to 2011 in 200 of the world’s largest metropolitan areas. The report found that these areas produced 48 percent of global output despite accounting for only 14 percent of the world’s population and employment.In other findings: Ninety percent of the fastest-growing economies were outside North America and western Europe; U.S. metropolitan areas outperformed t

    The Brookings Institution analyzed the financial data of the world’s largest metropolitan areas and uncovered some interesting findings. Check out which cities were the most productive.

  • Making Money Without the Speculation Rush Friday, 24 Feb 2012 | 5:32 PM ET

    Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.

  • Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.

  • Investors Crushin' on Rare Diseases     Tuesday, 14 Feb 2012 | 2:15 PM ET

    CNBC's Seema Moody reports on heightened interest in treating rare diseases as more patents expire. BioMarin Pharmaceutical is one of the leaders in this space, and its CEO Jean-Jacques Biename, weighs in.

  • Idenix CEO on Hep C Drug Study     Tuesday, 14 Feb 2012 | 8:16 AM ET

    Insight on the FDA clearing Idenix to resume study of its advanced experimental hepatitis C drug, with Ronald Renaud, Idenix president/CEO.

  • 6 Stocks Unworthy of Biotech Bull Market Wednesday, 8 Feb 2012 | 10:57 AM ET

    Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.

  • Cramer Slaps a ‘Buy’ on Biogen Friday, 27 Jan 2012 | 9:02 PM ET

    Find out why he’s bullish on this biotech name.

  • Cramer: Biogen Idec's Profit Pipeline     Thursday, 26 Jan 2012 | 6:25 PM ET

    Mad Money's Cramer, takes a look at Biogen Idec's medical breakthrough drugs and its near-term catalysts for growth this year.

  • Finerman's Fine Print: Roche Hostility     Wednesday, 25 Jan 2012 | 5:18 PM ET

    Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.